Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

VRML $1.30 0.1500 +13.04%
PBYI $35.61 3.0000 +9.20%
AGIO $52.63 4.2900 +8.87%
CALA $5.07 0.3500 +7.42%
MNKD $1.02 0.0600 +6.25%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KERX $5.70 -0.2100 -3.55%
BPTH $2.72 -0.1000 -3.55%
ALPMY $13.06 -0.4600 -3.40%
MACK $6.71 -0.2100 -3.03%
IDRA $1.56 -0.0400 -2.50%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Cancer Society Backs Lung Screening for Older, Heavy Smokers; Risks, Benefits Unknown for Rest

(Washington Post/Associated Press) Jan 11, 2013 - After decades of qualms about lung cancer screening, the American Cancer Society says there now is enough evidence to recommend it, but only for current and former heavy smokers ages 55 to 74 and after a frank talk about risks and benefits.
read article (free registration required) 

Morphotek Farletuzumab Phase III Study Fails to Meet Primary Endpoint

(Pharmaceutical Business Review) Jan 11, 2013 - Morphotek, a wholly-owned subsidiary of Eisai, has reported that farletuzumab in combination with carboplatin and a taxane failed to meet the primary endpoint of progression-free survival (PFS) in Phase III study.
read article 

ArQule, Daiichi's Colorectal Cancer Drug Fails Trial

(Reuters) Jan 11, 2013 - An experimental colorectal cancer drug being developed by ArQule Inc and Japan's Daiichi Sankyo Co Ltd failed to improve patient survival without the cancer worsening, in a mid-stage trial, sending ArQule's shares down 18 percent.
read article 

Drugmakers Report U.S. Shortages of Flu Vaccine, Tamiflu

(Reuters) Jan 10, 2013 - This year's early and potentially severe flu season has created shortages of the children's formulation of the leading treatment and most forms of the top-selling flu vaccine in the United States, according to their manufacturers.
read article 

More Doctors, Hospitals Partner to Coordinate Care for People with Medicare

(CMS) Jan 10, 2013 - Doctors and health care providers have formed 106 new Accountable Care Organizations (ACOs) in Medicare, ensuring as many as 4 million Medicare beneficiaries now have access to high-quality, coordinated care across the United States, Health and Human Services (HHS) Secretary Kathleen Sebelius announced today.
read press release 

Former Internet Pharmacist Sentenced in Fake Drug Case

(Wall Street Journal) Jan 9, 2013 - A pioneer of the Canadian Internet pharmacy business, Andrew Strempler, 38 years old, was sentenced in U.S. federal court in Miami to four years in prison for conspiracy to commit mail fraud in connection with the sale of foreign and counterfeit medicines to U.S. Customers.
read article (paid subscription required) 

FDA Requires Lower Doses for Ambien, Other Sleep Meds

(NBC News Vitals/Associated Press) Jan 10, 2013 - The Food and Drug Administration is requiring makers of Ambien and similar sleeping pills to lower the dosage of their drugs, based on studies suggesting patients face a higher risk of injury due to morning drowsiness.
read article 

FDA Issues Draft Guidance on Abuse-Deterrent Opioids

(FDA) Jan 9, 2013 - The U.S. Food and Drug Administration today issued a draft guidance document to assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
read press release 

Teva Asks FDA Not to Approve New MS Drugs Till Advisers Evaluate Safety

(Morningstar/Dow Jones Newswires) Jan 9, 2013 - Teva Pharmaceutical Industries Ltd., which sells the blockbuster multiple-sclerosis drug Copaxone, has asked the U.S. Food and Drug Administration not to approve any new MS drugs until their safety risks have been evaluated by outside advisers.
read article 

Blood Journal Celebrates Successful 2012, Welcomes New Editor-in-Chief for 2013

(ASH) Jan 9, 2013 - In 2012 Blood, the official journal of the American Society of Hematology (ASH), maintained its position as the most cited peer-reviewed publication in the field of hematology, publishing manuscripts detailing the most exciting basic, clinical, and translational hematology research breakthroughs.
read press release 

Fox Chase Cancer Center CEO, Other Top Executives Leaving

(Philadelphia Business Journal) Jan 10, 2013 - Major changes are coming in the leadership posts at Fox Chase Cancer Center, six months after the Philadelphia specialty hospital joined the Temple University Health System.
read article 

Moffitt Cancer Center Researchers Find Hispanics Lack Trust in Health Care Professionals, More Often Avoid Cancer Screenings

(Moffitt Cancer Center) Jan 3, 2013 - When researchers at Moffitt Cancer Center and colleagues conducted a random telephone survey among blacks, whites and Hispanics in New York, Baltimore and San Juan, Puerto Rico, they found that Hispanics are nearly twice as likely to report that fear of being used as a “guinea pig” and lack of trust in medical professionals contribute in being unwilling to participate in cancer screenings.
read press release 

Eli Lilly Settles Mass. Pregnancy Drug-Cancer Case

(ABC News/Associated Press) Jan 9, 2013 - Eli Lilly and Co. has settled a lawsuit brought by four sisters who contended their breast cancer was caused by a drug their mother took during pregnancy in the 1950s, a move some believe could trigger financial settlements in scores of other claims brought by women around the country.
read article 

Sickle Cells Show Potential to Attack Aggressive Cancer Tumors

(Duke Health) Jan 9, 2013 - By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors.
read article 

High Fiber Diet Prevents Prostate Cancer Progression

(UCCC blog) Jan 9, 2013 - A high-fiber diet may have the clinical potential to control the progression of prostate cancer in patients diagnosed in early stages of the disease.
read article 

Kaiser Permanente Study Suggests Tests Routinely Done on Patients with Microscopic Blood in Urine Can be Avoided

(Kaiser Permanente) Jan 9, 2013 - The presence of microscopic hematuria — blood found in urine that can’t be seen by the naked eye — does not necessarily indicate the presence of cancer, according to a Kaiser Permanente Southern California study published in the journal Mayo Clinic Proceedings.
read press release 

Smaller Radiation Fields Can Spare Brain When Treating Tumors

(Wake Forest Baptist) Jan 9, 2013 - New research from Wake Forest Baptist Medical Center shows that patients suffering from aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.
read press release 

New Tool to Help Brain Surgeons, One Step Closer to Operating Room

(Brigham and Women's Hospital) Jan 9, 2013 - A new tool that could allow for faster, more comprehensive testing of brain tissue during surgery successfully identified the cancer type, grade and tumor margins in five brain surgery patients, according to a new Brigham and Women's Hospital and Purdue University study.
read press release 

Poor People Participate in Cancer Trials Less Often

(Reuters Health) Jan 9, 2013 - Poor people are less likely to take part in clinical trials for new cancer drugs, which can make it harder to develop treatments, according to a new study.
read article 

Drug-Resistant Melanoma Tumors Shrink When Therapy Is Interrupted

(UCSF) Jan 9, 2013 - Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.
read article 

Breast Cancer Drug Trials 'Spun for Impact'

(The Telegraph UK) Jan 10, 2013 - Results of breast cancer drug trials are routinely ‘spun’ to make the treatments appear more beneficial than they actually are, doctors claim today.
read article 

Common Heart Drug Might Improve Lung Cancer Survival

(U.S. News & World Report/HealthDay News) Jan 9, 2013 - New research suggests that beta blockers, medications that are used to control blood pressure and heart rhythms, may also help lung cancer patients live longer.
read article 

Pfizer May Push $5 Billion Breast Cancer Hope for Ruling

(Bloomberg) Jan 10, 2013 - Pfizer Inc., the world’s largest drugmaker, is weighing whether to ask U.S. regulators to expedite their review of a potential $5 billion-a-year treatment to slow a type of incurable breast cancer.
read article 

Pap Test Could Help Find Cancers of Uterus and Ovaries

(New York Times) Jan 9, 2013 - The Pap test, which has prevented countless deaths from cervical cancer, may eventually help to detect cancers of the uterus and ovaries as well, a new study suggests.
read article 

China to Cut Prices of More Than 400 Drugs from February

(Yahoo! News/Reuters) Jan 8, 2013 - China will cut prices of about 400 drugs for respiratory diseases, fever and pain by up to 20 percent from February, in a move to make medicines, including some products from Pfizer, GlaxoSmithKline and Novartis, more affordable.
read article